Szu-Yao Kuo

Title: Szu-Yao Kuo: Innovator in Cancer Treatment

Introduction

Szu-Yao Kuo is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on developing peptide-conjugates that target tumor vasculature, providing new avenues for diagnosis and therapy.

Latest Patents

Kuo holds a patent for "Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment." This invention includes nucleic acids, peptides, and antibodies designed for applications in both diagnosis and therapy. The peptides specifically target neovasculature and were identified using in vivo phage display techniques. One notable peptide, SP5-52, has shown the ability to recognize the neovasculature of various tumors in SCID mice while sparing normal blood vessels. Additionally, this peptide binds to blood vessels in human lung cancer biopsy specimens. The combination of liposomes containing SP5-52 and doxorubicin has been found to enhance the drug's efficacy against multiple human cancer xenografts in SCID mice.

Career Highlights

Throughout his career, Szu-Yao Kuo has worked with esteemed institutions such as Academia Sinica and National Taiwan University. His research has garnered attention for its potential impact on cancer therapies, particularly in targeting tumor blood vessels.

Collaborations

Kuo has collaborated with notable colleagues, including Han-Chung Wu and Chin-Tarng Lin. Their joint efforts have contributed to advancing the understanding and treatment of cancer.

Conclusion

Szu-Yao Kuo's innovative work in developing peptide-conjugates for cancer treatment highlights his significant role in the field of medical research. His contributions continue to pave the way for new therapeutic strategies against cancer.